TABLE 10.
Summary of adverse events reported by ≥2 healthy participants dosed with crystalline ribavirin-PRINT-IP
| Preferred term |
n (%)a
|
||||
|---|---|---|---|---|---|
| Placebo (N = 4) | 60 mg, SD (N = 6) | 120 mg, SD (N = 6) | 30 mg, BID (N = 6) | 60 mg, BID (N = 12) | |
| Any AE | 4 (100) | 0 | 0 | 2 (33) | 8 (67) |
| Headacheb | 0 | 0 | 0 | 0 | 3 (25) |
| Malaise | 0 | 0 | 0 | 0 | 3 (25) |
| Feeling hot | 0 | 0 | 0 | 0 | 2 (17) |
| Vomiting | 0 | 0 | 0 | 0 | 2 (17) |
a
N, total number of participants; n, number of participants with observations.
b
Considered related to treatment by the investigator.